| Literature DB >> 36221145 |
Meg G Salvia1,2, Marilyn D Ritholz3,4, Katherine L E Craigen5, Paula A Quatromoni6,7.
Abstract
BACKGROUND: The overlap in prevalence between type 2 diabetes and binge eating disorder is substantial, with adverse physical and mental health consequences. Little is known about patients' efforts at managing these two conditions simultaneously. The research objective was to explore patients' experiences managing co-existing type 2 diabetes or prediabetes and binge eating disorder.Entities:
Keywords: Binge eating disorder; Eating disorder treatment; Prediabetes; Qualitative research; Type 2 diabetes
Year: 2022 PMID: 36221145 PMCID: PMC9554983 DOI: 10.1186/s40337-022-00666-y
Source DB: PubMed Journal: J Eat Disord ISSN: 2050-2974
Fig. 1Screening and recruitment of BED patients
Participant characteristics (n = 21 women)
| Mean (range) | N (%) | |
|---|---|---|
| Participant age, in years | ||
| Mean (range) | 49 (19–66) | |
| Participant race | ||
| White | 19 (90) | |
| Black or African American | 1 (5) | |
| Multiple race identities indicated | 1 (5) | |
| BMI | ||
| Mean (range) | 43.8 (30.2–63.9) | |
| 30.0-39.9 | 7 (33) | |
| 40.0-49.9 | 10 (48) | |
| 50.0-59.9 | 3 (14) | |
| 60.0-69.9 | 1 (5) | |
| Education history | ||
| Completed high school | 1 (5) | |
| Some college or technical school | 6 (29) | |
| College degree | 11 (52) | |
| Graduate degree | 3 (14) | |
| Employment status | ||
| Employed, full-time | 10 (48) | |
| Employed, part-time | 5 (24) | |
| Disabled, employed part-time | 1 (5) | |
| Disabled, not able to work | 4 (19) | |
| Student | 3 (14) | |
| Insurance plan (at time of interview) | ||
| Medicaid or Medicare | 5 (24) | |
| Group/private insurance through employer | 13 (62) | |
| Individual private insurance (self-purchased) | 3 (14) | |
| Treatment team composition (at time of interview) | ||
| Primary care (physician or nurse practitioner) | 21 (100) | |
| Therapist | 11 (52) | |
| Dietitian | 4 (19) | |
| Endocrinologist | 7 (33) | |
| Diabetes educator | 1 (5) | |
| Psychiatrist | 8 (38) |
Participants’ diabetes and binge eating outcomes (n = 21)
| Characteristic | Mean (range) | N (%) | |
|---|---|---|---|
| Diabetes diagnosis | |||
| Type 2 diabetes | 10 (48) | ||
| Current hemoglobin A1c (%) | 8.4 (6.4–14.0) | ||
| Diabetes duration (years) | 12 (5–18) | ||
| Insulin use (% yes)* | 3 (15) | ||
| Non-insulin T2DM medication use (% yes)* | 9 (45) | ||
| Metformin | 8 | ||
| Sulfonylurea | 2 | ||
| Thiazolidinedione | 1 | ||
| DPP-4 inhibitor | 1 | ||
| GLP-1 receptor agonist | 1 | ||
| SGLT2 inhibitor | 1 | ||
| Prediabetes | 11 (52) | ||
| Years since prediabetes diagnosis | 5.7 (1–19) | ||
Number progressing to T2DM diagnosis | 1 (9) | ||
| Age/Life stage of binge onset (self-reported) | |||
| Childhood | 11 (52) | ||
| Adolescence | 4 (19) | ||
| Young adulthood | 4 (19) | ||
| Middle adulthood | 2 (10) | ||
Frequency of binge eating episodes (at time of interview) | |||
| < 1x/month | 5 (24) | ||
| 1-2x/month | 2 (10) | ||
| 1x/week | 4 (19) | ||
| 2-3x/week | 3 (14) | ||
| 4-6x/week | 2 (10) | ||
| 1x/day | 3 (14) | ||
| > 1x/day | 2 (10) | ||
| EDE-Q scores** | |||
| Global Score | 2.6 (0.6–5.3) | ||
| Restraint | 1.5 (0–3.6) | ||
| Eating concern | 2.5 (0–6) | ||
| Shape concern | 3.1 (0.3–6) | ||
| Weight concern | 3.5 (0.5–6) | ||
*One participant with T2DM declined to list medications; the sample size for the medication data points is 20. Some reported taking multiple non-insulin diabetes medications. Abbreviations include: sodium-glucose cotransporter-2 (SGLT2), dipeptidyl peptidase 4 (DPP-4), glucagon-like peptide-1 (GLP-1)
**EDE-Q global and subscale scores range from 0–6; higher number indicates more problematic eating behaviors and attitudes; a cut-off of 4 on the global score generally represents clinical significance [28]
Fig. 2Strategies for synthesizing BED and T2DM treatment recommendations